Accelerating Targeted Protein Degrader

Drug Discovery with Precision and Efficiency

Join us at the

TPD & Induced proximity summit,

Boston, Oct 28-31, 2024

Meet us at the conference and let's talk about potential opportunities to collaborate

Vision

Transform human health by unlocking the undruggable proteome

WHY INTERPLAY BIO?

Interplay Bio has developed LigandPro Platform for accelerating the development of TPD drugs


LigandPro's advanced capabilities offer significant advantages in the drug discovery process

Target any Protein Surface

LigandPro identifies ligands that can bind to any surface on a protein, not just the traditional druggable pockets leading to targeting of undruggable proteome.


LigandPro’s ability to identify the poly-pharmacology and ALL small-molecule protein interactions accelerates safety profiles and dosage optimization


Leverage Existing Protein Libraries

LigandPro's ability to utilize existing protein libraries for small molecule hit identification enables rapid screening against a vast array of potential targets.


Our hypothesis free approach enables exploration of a wide range of protein targets, significantly increasing the possibility of finding new hits, even for “difficult to drug” proteins.


We can also use the screening platform to screen small molecules for binding with specific targets. 

Discover New E3 Ligase Binders

and Molecular Glues

Rationally expand the Molecular Glue Degraders that you utilize, achieving higher specificity and safety profiles

How can Interplay Bio help?

We are actively seeking collaborations with partner organization in the following areas

Target Ligand Discovery

Utilize our LigandPro platform to explore potential opportunities for existing molecule libraries for further exploitation using the TPD modalities. In addition, we can identify and exploit the polypharmacology of drugs, enabling the targeting of multiple related proteins

Learn More

Pipeline of Innovative E3 Ligands

We have identified two molecules with high potential for PDAC. Collaborate with us to develop these as TPDs and take them to market. In addition, we also have a proprietary pipeline of 30 new small molecule-protein interactions

Learn More

E3 Ligase Binders and Molecular Glue Development

We have a unique approach to develop new E3 Ligase binders and Molecular Glues. Through these approaches, we identified several new E3 Ubiquitin & Sumo E3 Ligases, Deubiquitinases (DUBs), collaborate with us for developing new proprietary binders and glues

Learn More
Share by: